An important work performed by Goltz used data from 470 melanoma patients provided by The Cancer Genome Atlas and a cohort of 50 metastatic melanoma patients treated with anti–PD-1 or/and anti–CTLA-4 antibodies, to investigate if CTLA-4 promoter methylation profile can be used as a biomarker to predict more successful treatment with ICB (immune checkpoint blockage). This evidence concerns the gene CTLA4 and melanoma.